Global data dive: how immunotherapy fights advanced kidney cancer

NCT ID NCT05287464

Recruiting now Knowledge-focused Sponsor: Hospital of Macerata Source: ClinicalTrials.gov ↗

First seen Jan 10, 2026 · Last updated May 15, 2026 · Updated 13 times

Summary

This study looks back at medical records from 1220 people with advanced kidney cancer who received immunotherapy combinations as their first treatment. The goal is to learn how well these treatments work and how they affect different groups, like older patients or those with cancer spread to the brain or bones. No new drugs or treatments are given—researchers are simply gathering and analyzing existing data to improve future care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA (MRCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ospedale di Macerata, UOC Oncologia
RECRUITING

Province of Macerata, Macerata, 62100, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Contact

Conditions

Explore the condition pages connected to this study.

METASTATIC RENAL CELL CARCINOMA (MRCC)